Juneko Grilley Olson, MD
Hematology & Oncology · Chapel Hill, NCNPI 1417074204
Payments from drug & device makers
Across 237 payments — averaging $4354.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- PTC Therapeutics, Inc.$320K
- Seagen Inc.$277K
- E.r. Squibb & Sons, L.L.C.$125K
- Pfizer$89K
- Boehringer Ingelheim$75K
- Incyte Corporation$58K
- plus $88K from 10 others
Across 6 payments — averaging $1586.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10K
What the payments were for
- Consulting fees$3,02313%
- Speaking & faculty fees$16,90572%
- Travel & lodging$2,0439%
- Food & beverage$1,5447%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| PTC Therapeutics, Inc. | 26 | $320,345 |
| Seagen Inc. | 72 | $276,734 |
| E.r. Squibb & Sons, L.L.C. | 2 | $125,000 |
| Pfizer | 17 | $89,423 |
| Boehringer Ingelheim | 6 | $74,700 |
| Incyte Corporation | 53 | $57,756 |
| AstraZeneca | 1 | $39,781 |
| Genentech, Inc. | 16 | $18,630 |
| Deciphera Pharmaceuticals Inc. | 16 | $9,432 |
| Bayer | 11 | $7,847 |
| Aadi Bioscience, Inc. | 7 | $5,452 |
| Ipsen Biopharmaceuticals, Inc | 6 | $5,096 |
| Daiichi Sankyo Inc. | 1 | $1,013 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $568 |
| Exelixis Inc. | 1 | $174 |
| Springworks Therapeutics, Inc. | 1 | $123 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,032,073 in reported general payments places this provider in the 85th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 20 | $4,201 |
| Prochlorperazine Maleate | 17 | $176 |
| Ondansetron Hcl | 15 | $132 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Chapel Hill
- Joshua ZeidnerChapel Hill$11.2M
- Jared WeissChapel Hill$7.3M
- Autumn McReeChapel Hill$5.5M
- Christopher DittusChapel Hill$4.7M
- Eben LichtmanChapel Hill$3M
- Brandi ReevesChapel Hill$2.7M
- Jonathan SerodyChapel Hill$1.6M
- William WoodChapel Hill$1.1M
- Nigel KeyChapel Hill$872K
- Thomas SheaChapel Hill$713K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.